Please login to the form below

Not currently logged in
Email:
Password:

Zoladex

This page shows the latest Zoladex news and features for those working in and with pharma, biotech and healthcare.

After MYSTIC setback, FDA gives some comfort to AZ

After MYSTIC setback, FDA gives some comfort to AZ

expansion of a facility in Macclesfield intended to support high demand for prostate cancer drug Zoladex.

Latest news

  • Grünenthal buys Zomig rights as AZ slimming drive continues Grünenthal buys Zomig rights as AZ slimming drive continues

    This work has seen it agree deals with TerSera Therapeutics ($320m for Zoladex), ProStakan ($70m for Moventig), Aspen ($770m for seven anaesthetics drugs) and, most recently, Recordati ($300m for two blood

  • AZ agrees to $320m deal for Zoladex AZ agrees to $320m deal for Zoladex

    ongoing. A further $70m is also up for grabs should Zoladex (goserelin acetate implant) meet a series of sales-related milestones. ... It also ensure patients have continued access to Zoladex, with TerSera's dedicated focus helping to expand the

  • Roche maintains dominance as leading cancer drugmaker Roche maintains dominance as leading cancer drugmaker

    AZ saw sales fall across much of its oncology brands, with a 4% decline for its biggest cancer seller Zoladex (goserelin) for certain breast cancers with revenue just shy of being

  • AZ invests £120m in UK cancer drug production AZ invests £120m in UK cancer drug production

    The new building in Macclesfield, Cheshire will focus on the production of prostate cancer treatment Zoladex (gosrelin), which has annual sales of around $1bn. ... Zoladex has been manufactured in Macclesfield for more than 25 years and AZ said the new

  • FDA insists on GnRH agonists risk warning

    They are sold as Lupron (manufactured by Abbott), Zoladex (AstraZeneca), Trelstar (Watson), Viadur (Alza), and Eligard (sanofi-aventis) as well as under several generic labels.

More from news
Approximately 2 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    First approved in North America in 1989, Zoladex sales in 2016 were $69m in the US and Canada and $816m globally. ... Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex, goserelin acetate implant for prostate, breast cancer, benign gynaecological

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics